Summary & Overview
HCPCS J1203: Injection, cipaglucosidase alfa-atga, 5 mg
HCPCS Level II code J1203 denotes a 5 mg vial of cipaglucosidase alfa-atga, an intravenous enzyme replacement therapy used for specific metabolic disorders. Nationally, biologic infusion products like cipaglucosidase alfa attract attention for their clinical complexity, cost implications, and specialized site-of-service requirements, making accurate coding critical for clinical documentation and payer reimbursement. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find an overview of the clinical role of cipaglucosidase alfa-atga, typical service settings, and what to expect in terms of coding application for a 5 mg unit. The publication summarizes payer coverage patterns, common billing modifiers, and operational considerations for administering and billing this injectable biologic. It also outlines benchmark elements and recent policy updates that affect billing and prior authorization processes for high-cost infusion therapies. Practical insights are provided for revenue cycle and clinical teams to align documentation, infusion protocols, and claims submission for HCPCS Level II code J1203 in a national context.
Billing Code Overview
HCPCS Level II code J1203 represents an injectable biologic product: injection, cipaglucosidase alfa-atga, 5 mg. This code covers administration of a 5 mg unit of cipaglucosidase alfa-atga, an enzyme replacement therapy formulation intended for intravenous infusion.
Service Type: Intravenous infusion of a biologic enzyme replacement
Typical Site of Service: Hospital outpatient infusion center or ambulatory infusion clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with confirmed late-onset Pompe disease (glycogen storage disease type II) presents to an outpatient infusion center for enzyme replacement therapy. The patient is an adult receiving J1203 (cipaglucosidase alfa-atga) in 5 mg vial(s) per the prescribing regimen. The clinical workflow includes pre-infusion nursing assessment (vital signs, weight, review of prior infusion tolerance), verification of medication and dose by pharmacy (reconstitution and labeling), baseline laboratory review (including CK and pulmonary function trend), and placement of an IV access. Infusion is administered under direct nursing supervision with monitoring for infusion-related reactions; emergency medications and oxygen are immediately available. Post-infusion observation is performed for a period appropriate to the patient’s prior infusion history and clinical status. Documentation includes medication lot number, dose administered, infusion start and stop times, any premedication and reactions, and billing with appropriate HCPCS J1203 and clinically applicable modifiers and diagnosis codes that support enzyme replacement therapy for Pompe disease.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When part of a single-use vial of is wasted and payer requires reporting of discarded drug |